<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: To determine whether <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risks for carriers and noncarriers from families with a mismatch repair (MMR) gene mutation are increased above the risks of the general population </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: We prospectively followed a cohort of 446 unaffected carriers of an MMR gene mutation (MLH1, n = 161; MSH2, n = 222; MSH6, n = 47; and PMS2, n = 16) and 1,029 their unaffected relatives who did not carry a mutation every 5 years at recruitment centers of the <z:hpo ids='HP_0003003'>Colon Cancer</z:hpo> Family Registry </plain></SENT>
<SENT sid="2" pm="."><plain>For comparison of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> risk with the general population, we estimated country-, age-, and sex-specific standardized incidence ratios (SIRs) of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> for carriers and noncarriers </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Over a median follow-up of 5 years, mutation carriers had an increased risk of <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>; SIR, 20.48; 95% CI, 11.71 to 33.27; P &lt; .001), <z:e sem="disease" ids="C0476089" disease_type="Neoplastic Process" abbrv="">endometrial cancer</z:e> (SIR, 30.62; 95% CI, 11.24 to 66.64; P &lt; .001), <z:e sem="disease" ids="C1140680" disease_type="Neoplastic Process" abbrv="">ovarian cancer</z:e> (SIR, 18.81; 95% CI, 3.88 to 54.95; P &lt; .001), <z:e sem="disease" ids="C0740457" disease_type="Neoplastic Process" abbrv="">renal cancer</z:e> (SIR, 11.22; 95% CI, 2.31 to 32.79; P &lt; .001), <z:hpo ids='HP_0002894'>pancreatic cancer</z:hpo> (SIR, 10.68; 95% CI, 2.68 to 47.70; P = .001), <z:hpo ids='HP_0012126'>gastric cancer</z:hpo> (SIR, 9.78; 95% CI, 1.18 to 35.30; P = .009), <z:e sem="disease" ids="C0699885,C0005684" disease_type="Neoplastic Process" abbrv="">urinary bladder cancer</z:e> (SIR, 9.51; 95% CI, 1.15 to 34.37; P = .009), and female <z:hpo ids='HP_0003002'>breast cancer</z:hpo> (SIR, 3.95; 95% CI, 1.59 to 8.13; P = .001) </plain></SENT>
<SENT sid="4" pm="."><plain>We found no evidence of their noncarrier relatives having an increased risk of any <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e>, including <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> (SIR, 1.02; 95% CI, 0.33 to 2.39; P = .97) </plain></SENT>
<SENT sid="5" pm="."><plain>CONCLUSION: We confirmed that carriers of an MMR gene mutation were at increased risk of a wide variety of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e>, including some <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancers</z:e> not previously recognized as being a result of MMR mutations, and found no evidence of an increased risk of <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> for their noncarrier relatives </plain></SENT>
</text></document>